Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage
- PMID: 30616027
- PMCID: PMC6609497
- DOI: 10.1016/j.cgh.2018.12.031
Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage
Abstract
Background & aims: Noninvasive methods are needed to determine disease stage in patients with nonalcoholic fatty liver disease (NAFLD). We evaluated the diagnostic performance of several widely available fibrosis models for the assessment of hepatic fibrosis in patients with NAFLD.
Methods: We performed a retrospective analysis of data from individuals enrolled in the NIDDK NASH Clinical Research Network, from 2004 through 2018. Using biopsy as the reference standard, we determined the diagnostic performance of the aspartate aminotransferase (AST):platelet ratio (APRI), FIB-4, ratio of AST:alanine aminotransferase (ALT) and the NAFLD fibrosis score (NFS) in a cross-sectional study of 1904 subjects. The ability of these models to detect changes in fibrosis stage was assessed in a longitudinal data set of 292 subjects with 2 biopsies and accompanying laboratory data. Outcomes were detection of fibrosis of any stage (stages 0-4), detection of moderate fibrosis (stages 0-1 vs 2-4), and detection of advanced fibrosis (stages 0-2 vs 3-4). Diagnostic performance was evaluated using the C-statistic, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) analyses.
Results: In the cross-sectional study, FIB-4 and NFS outperformed other non-invasive models for detecting advanced fibrosis; the C-statistics were 0.80 for FIB-4 and 0.78 for NFS. In the longitudinal study, 216 patients had non-advanced fibrosis at baseline and 35 patients progressed to advanced fibrosis after median follow up of 2.6 years. After we adjusted for fibrosis stage and model score at initial biopsy, change in APRI, FIB-4, and NFS were significantly associated with change in fibrosis. A unit change in APRI, FIB-4, or NFS was associated with changes in fibrosis stage of 0.33 (95% CI, 0.20-0.45; P < .001), 0.26 (95% CI, 0.15-0.37; P < .001), and 0.19 (95% CI, 0.07-0.31; P = .002), respectively. The cross-validated C-statistic for detecting progression to advanced fibrosis for APRI was 0.82 (95% CI, 0.74-0.89), for FIB-4 was 0.81 (95% CI, 0.73-0.81), and for NFS was 0.80 (95% CI, 0.71-0.88).
Conclusions: In a combined analysis of data from 2 large studies, we found that FIB-4, APRI, and NFS can detect advanced fibrosis and fibrosis progression in patients with NAFLD.
Keywords: Diagnostic; Nonalcoholic Steatohepatitis; Prognostic; Scoring System Comparison.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures
Similar articles
-
Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.Dig Dis Sci. 2018 Sep;63(9):2259-2266. doi: 10.1007/s10620-018-5123-3. Epub 2018 May 19. Dig Dis Sci. 2018. PMID: 29779083
-
Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease.Clin Transl Gastroenterol. 2020 Apr;11(4):e00165. doi: 10.14309/ctg.0000000000000165. Clin Transl Gastroenterol. 2020. PMID: 32352687 Free PMC article.
-
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.Am J Gastroenterol. 2017 May;112(5):740-751. doi: 10.1038/ajg.2016.453. Epub 2016 Oct 11. Am J Gastroenterol. 2017. PMID: 27725647 Free PMC article.
-
Liver fibrosis stage based on the four factors (FIB-4) score or Forns index in adults with chronic hepatitis C.Cochrane Database Syst Rev. 2024 Aug 13;8(8):CD011929. doi: 10.1002/14651858.CD011929.pub2. Cochrane Database Syst Rev. 2024. PMID: 39136280 Review.
-
Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis.Hepatology. 2015 Jan;61(1):292-302. doi: 10.1002/hep.27382. Epub 2014 Nov 24. Hepatology. 2015. PMID: 25132233 Review.
Cited by
-
The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH.Hepatology. 2019 Dec;70(6):1885-1888. doi: 10.1002/hep.30946. Hepatology. 2019. PMID: 31520407 Free PMC article. No abstract available.
-
Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?Clin Diabetes Endocrinol. 2020 Jun 5;6:9. doi: 10.1186/s40842-020-00097-1. eCollection 2020. Clin Diabetes Endocrinol. 2020. PMID: 32518675 Free PMC article. Review.
-
Embedding assessment of liver fibrosis into routine diabetic review in primary care.JHEP Rep. 2021 Apr 22;3(4):100293. doi: 10.1016/j.jhepr.2021.100293. eCollection 2021 Aug. JHEP Rep. 2021. PMID: 34179738 Free PMC article.
-
Socioeconomic status and health disparities drive differences in accelerometer-derived physical activity in fatty liver disease and significant fibrosis.PLoS One. 2024 May 9;19(5):e0301774. doi: 10.1371/journal.pone.0301774. eCollection 2024. PLoS One. 2024. PMID: 38722965 Free PMC article.
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.Front Nutr. 2024 Feb 14;11:1284509. doi: 10.3389/fnut.2024.1284509. eCollection 2024. Front Nutr. 2024. PMID: 38419854 Free PMC article.
References
-
- Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84. - PubMed
-
- Kleiner DE, Brunt EM, Natta M Van, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–1321. - PubMed
-
- Kruger FC, Daniels CR, Kidd M, et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J 2011;101:477–480. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 DK061731/DK/NIDDK NIH HHS/United States
- U01 DK061718/DK/NIDDK NIH HHS/United States
- U01 DK061728/DK/NIDDK NIH HHS/United States
- U01 DK061738/DK/NIDDK NIH HHS/United States
- U01 DK061734/DK/NIDDK NIH HHS/United States
- KL2 TR002648/TR/NCATS NIH HHS/United States
- U01 DK061737/DK/NIDDK NIH HHS/United States
- U01 DK061713/DK/NIDDK NIH HHS/United States
- U01 DK061732/DK/NIDDK NIH HHS/United States
- UL1 TR002548/TR/NCATS NIH HHS/United States
- U01 DK061730/DK/NIDDK NIH HHS/United States
- U24 DK061730/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical